Evidence map›Paper›PMID 35944850›Full record

ArticleBioorganic & medicinal chemistry letters2022

Development and profiling of mGlu

Carson W Reed, Alice L Rodriguez, Jacob J Kalbfleisch, Mabel Seto, Matthew T Jenkins, Anna L Blobaum, Sichen Chang, Craig W Lindsley, Colleen M Niswender

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Profiling the Impact of mGluACS chemical neuroscience · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carson W ReedDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Alice L RodriguezDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Jacob J KalbfleischDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Mabel SetoDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Matthew T JenkinsDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Anna L BlobaumDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Sichen ChangDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States; Vanderbilt Institute for Chemical Biology, Vanderbilt University, Nashville, TN 37232, United States; Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Vanderbilt Department of Chemistry, Vanderbilt University, Nashville, TN 37232, United States.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, United States; Vanderbilt Institute for Chemical Biology, Vanderbilt University, Nashville, TN 37232, United States; Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232, United States. Electronic address: colleen.niswender@vanderbilt.edu.

Funding

Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disordersR01MH124671 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2020 to 2024
$3.5M
Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator ProbeR01MH113543 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2017 to 2019
$1.2M
Metabotropic Glutamate Receptor Regulation in MeCP2-Related DisordersR21MH102548 · NIMH · VANDERBILT UNIVERSITY · PI NISWENDER, COLLEEN M · 2014 to 2015
$431k
NIMH NIH HHS R01 MH113543NIMH NIH HHS R01 MH124671NIMH NIH HHS R21 MH102548
6 · The paper itself

Abstract

We describe here a series of metabotropic glutamate receptor 7 (mGlu

Indexed as

Allosteric RegulationLigandsLigandsMetabotropic glutamate receptormGlu(7)Positive Allosteric modulator (PAM)Structure Activity Relationship (SAR)

Identifiers

PMID35944850
PMCPMC10015594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.